Zydus Lifesciences Q1 FY27 Results Analysis: PAT Falls 36%, EBITDA Margin Compresses 770 bps (ZYDUSLIFE)
Zydus Lifesciences Ltd's Q1 FY27 numbers came in mixed, with revenue of Rs. 8,017.00 Cr (+21.96% YoY) and PAT growth of -35.93% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | August 11, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Revenue (Q1) | Rs. 8,017.00 Cr (+21.96% YoY) |
| PAT (Q1) | Rs. 939.80 Cr (-35.93% YoY) |
| EBITDA margin | 24.07% (-770 bps YoY) |
| EPS (Q1) | Rs. 9.35 (-35.87% YoY) |
| Market cap | Rs. 117,526.90 Cr |
| CMP | Rs. 1,180.00 |
Quarter Snapshot
Revenue grew 22% YoY to a record Rs.8,017 Cr, driven by acquisitions, but margins compressed sharply (EBITDA margin down 770 bps) and PAT declined 36% due to integration costs, higher employee and finance costs, and US generic pricing pressure. Management's FY27 guidance of >24% EBITDA margin was achieved at the lower end, but organic pharma profitability remains under strain.
Key Investment Insights
Key Positives
- Consolidated revenue grew 21.96% YoY to Rs.8,017.0 Cr, highest Q1 revenue on record
- Consumer products revenue surged 67.45% YoY to Rs.1,435.9 Cr, driven by Comfort Click acquisition
- Medical technologies revenue increased from Rs.2 Cr to Rs.283 Cr due to Amplitude Surgical consolidation
- Pharma segment revenue grew 10.22% YoY to Rs.6,298.1 Cr despite US generic pricing pressure
- Company completed Assertio acquisition on June 16, 2026, adding ~15 days of revenue
- Normalized PAT (excluding exceptional items) estimated at Rs.953.1 Cr
Risk Factors
- EBITDA margin compressed 770 bps YoY to 24.07%
- PAT (to owners) declined 35.93% YoY to Rs.939.8 Cr
- Pharma segment EBIT margin fell 1,263 bps YoY to 19.77% due to US generic competition and acquisition costs
- Finance costs surged 84.2% YoY to Rs.156 Cr due to acquisition debt
- Employee costs rose 36.1% YoY, outpacing revenue growth
- Depreciation & amortisation jumped 133% YoY to Rs.555 Cr, partly due to Mirabegron amortisation
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.